Robert Langer (Barry Chin/The Boston Globe via Getty Images)

MIT’s fa­bled bil­lion­aire sci­en­tist Robert Langer is step­ping in to of­fer a key as­sist to Ovid CEO Je­re­my Levin

Je­re­my Levin’s biotech start­up Ovid suf­fered a crip­pling blow late last year when the CEO was forced to con­cede that the crit­ics were right all along and his lead drug was a bust in a late-stage test. But he’s gained an im­por­tant as­sist in get­ting back up again and re­fo­cus­ing on oth­er drugs in the pipeline.

Fa­bled MIT in­ves­ti­ga­tor and se­r­i­al en­tre­pre­neur Robert Langer has signed on to chair the sci­en­tif­ic board for Ovid, of­fer­ing some guid­ance a day af­ter Levin of­fi­cial­ly iced both pro­grams for OV101. Ovid li­censed out their sec­ond drug in the pipeline to Take­da, leav­ing a pre­clin­i­cal ef­fort in place for a slate of drugs that in­cludes OV882, a short hair­pin RNA ther­a­py tar­get­ing UBE3A gene ex­pres­sion in neu­rons.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.